Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Cubist Pharma Q1 Profit Rises - Quick Facts

Cubist Pharmaceuticals, Inc. (CBST: Quote) Wednesday reported a higher profit for the first quarter as revenues increased 30 percent.

The Lexington, Massachusetts-based company reported a first-quarter net profit of $32.79 million or $0.45 per share, compared to $22.59 million or $0.34 per share last year.

Adjusted net income for the quarter rose to $66.31 million or $0.82 per share from $41.20 million or $0.54 per share in the prior-year quarter.

On average, 14 analysts polled by Thomson Reuters expected the company to earn $0.44 per share for the quarter. Analysts' estimates typically exclude special items.

Total revenues for the quarter grew 30 percent to $211.69 million from $162.53 million in the prior-year quarter. Fourteen analysts had a consensus revenue estimate of $209.42 million for the quarter.

Click here to receive FREE breaking news email alerts for Cubist Pharmaceuticals Inc and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.